Esketamine, an antagonist of the N-methyl-D-aspartate (NMDA) receptor, was first granted an FDA breakthrough therapy designation for treatment-resistant depression in 2013 and for major depressive disorder with risk of suicide in 2016. According to Janssen, the decision by the FDA on whether to approve the medication is expected by March 4.
https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2018.17060720
http://alert.psychnews.org/ (2019-2-13)
